cd3/cd19 negative allogeneic hematopoietic stem cells
Severe Combined Immunodeficiency
Explore 14 assets in Severe Combined Immunodeficiency →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Paul Szabolcs
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01852370CT.gov Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Severe Combined Immunodeficiency
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd3/cd19 negative allogeneic hematopoietic stem cells (this asset) | Paul Szabolcs | P1/2 | CCC · 48 |
| Fludarabine | National Institute of Allergy and Infectious Diseases (NIAID) | P2/3 | BB |
| Nivestim | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | BB |
| Alemtuzumab | Washington University School of Medicine | P2/3 | BB |
| Busulfanum | National Institute of Allergy and Infectious Diseases (NIAID) | P2/3 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2/3 | BB |
| Elapegademase | Leadiant Biosciences, Inc. | P3 | BB |
| Autologous Cd34+ Cells Transduced With Tns9.3.55 | National Institute of Allergy and Infectious Diseases (NIAID) | P1/2 | BB |
| Thiotepa | St. Jude Children's Research Hospital | P2 | BB |
+22 more in the Severe Combined Immunodeficiency cohort
Other indications for cd3/cd19 negative allogeneic hematopoietic stem cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hyper-IgE Syndrome | — | P1/2 | CCC · 48 |
| T-Cell Immunodeficiency | — | P1/2 | CCC · 48 |
| Severe Congenital Neutropenia | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FludarabineNational Institute of Allergy and Infectious Diseases (NIAID)BB
- NivestimNational Institute of Allergy and Infectious Diseases (NIAID)BB
- AlemtuzumabWashington University School of MedicineBB
- BusulfanumNational Institute of Allergy and Infectious Diseases (NIAID)BB
- CyclophosphamideSt. Jude Children's Research HospitalBB
Citation
Floatz Terminal. cd3/cd19 negative allogeneic hematopoietic stem cells in Severe Combined Immunodeficiency. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd3cd19-negative-allogeneic-hematopoietic-stem-cells-severe-combined-immunodeficiency
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →